Non-ischemic cardiomyopathies are a heterogeneous group of diseases of the myocardium that have a distinct proclivity to ventricular arrhythmias. Of these, ventricular tachycardia pose significant management challenges with the risk of sudden cardiac death. Although implanted cardiac defibrillators may prevent sudden death from ventricular tachycardia, non-ischemic cardiomyopathy patients may suffer from recurrent symptoms and debilitating hardware shocks, and anti-arrhythmic drug side effects. Under these conditions, radiofrequency ablation of ventricular tachycardia is becoming an increasingly utilised intervention that has been found to have significant benefits with improving symptoms, reducing anti-arrhythmic drug burden and debilitating device therapies, thereby improving quality of life. Nonetheless, the approach to the ablation of ventricular tachycardia in nonischemic cardiomyopathies is governed heavily by the disease process, with several distinct differences from ischemic cardiomyopathy including a preponderance to epicardial and deep intramural substrate. Determining the localization of the substrate is an important basis for successful treatment. Non-invasive diagnostic techniques, able to identify the substrate, including a 12-lead electrocardiogram and the distribution of late gadolinium amplification on cardiac magnetic resonance imaging, play a key role in choosing the optimal strategy for interventional therapy. The use of these techniques in catheter ablation holds promising prospects for the future. This current review will summarise the incidence, mechanism, and multimodal assessment of ventricular arrhythmias in patients with non-ischemic cardiomyopathy.